Whittier Trust Co. of Nevada Inc. Has $11.65 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Whittier Trust Co. of Nevada Inc. raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,182 shares of the medical research company’s stock after acquiring an additional 1,026 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in IQVIA were worth $11,654,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Versant Capital Management Inc increased its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA during the second quarter worth $27,000. Park Place Capital Corp acquired a new stake in IQVIA during the third quarter valued at $28,000. Itau Unibanco Holding S.A. acquired a new stake in IQVIA in the second quarter valued at approximately $29,000. Finally, Riverview Trust Co bought a new stake in IQVIA in the first quarter worth approximately $32,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV traded down $5.66 on Monday, hitting $231.03. The company’s stock had a trading volume of 457,602 shares, compared to its average volume of 1,063,540. The company has a 50 day moving average price of $239.08 and a 200 day moving average price of $231.08. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a market capitalization of $42.12 billion, a PE ratio of 30.74, a PEG ratio of 2.22 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same period last year, the company posted $2.22 earnings per share. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent research reports. Barclays decreased their price objective on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a report on Tuesday, October 15th. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Monday, October 14th. UBS Group boosted their price target on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Morgan Stanley lifted their price objective on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $267.87.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.